

Event-History Data Problems in Differential Diagnosis: Clinical Applications from Apudoma- Caused Hypertension

A.L. Long, PhD

International Network Services

H.H. Whitman III, MD, FACP, FACR

**New York Presbyterian – Weill Cornell Medical Center for
Hypertension; Summit Medical Group, Chief, Department
of Rheumatology ; and Hospital for Special Surgery**

C.J. Gelber, MD

Summit Medical Group, Chief, Department of Nephrology

June 7, 2006

Event-history data on hypertension: Differential diagnosis of apudoma?

- **Primary HPT (90%)**
- **Bilateral renal parenchymal disease (5%)**
 - *Chronic glomerulonephritis*
 - *Interstitial nephritis*
 - *Polycystic disease*
 - *Diabetic nephropathy*
 - *Systematic lupus erythematosus*
 - *Amyloidosis*
 - *Multiple myeloma*
 - *Scleroderma*
 - *Wegener's granulomatosis*
 - *Goodpasture's disease*
 - *Periarteritis nodosa*
 - *Takayasu's arteritis*
 - *Vasculitis*
 - *Balkan nephritis*
 - *Congenital renal disease*
- *Italics = Have no catecholamine and/or other metabolite excess*
- **Starred = May have paroxysmal HPT**
- **Red = Apudoma (amine precursor uptake and decarboxylation) cells**
- **Other diastolic HPT causes (5%)**
 - *Acute multiple sclerosis*
 - *Fatal familial insomnia*
 - *Spinal cord lesion **
 - *Acute intermittent porphyria **
 - *Acute bulbar poliomyelitis **
 - *Baroreflex failure **
 - *Cushing's disease or syndrome*
 - *Renal/ renin-secreting tumor*
 - *Acute coronary insufficiency +/- myocardial infarct) **
 - *Hypersensitivity reactions **
 - *Hypothalamic tumor **
 - *Fibrosarcoma in pulmonary artery **
 - ***Pheochromocytoma ****
 - ***Neuroblastoma */ Ganglioneuroma ****
 - ***Gastroenteropancreatic neuroendocrine tumor ****
 - *Intracranial-pressure-causing lesions **
 - *Guillain-Barre syndrome **
 - *Hypoglycemia **
 - *Clonidine withdrawal*
 - *Mastocytosis*

Sample within-group lab tests showing spottiness of data

TABLE 1. Plasma Biochemical Tests (chronological order) in

a patient with secondary hypertension, unknown cause

Date	Dopamine Frac Plasma (pg/mL)	Norepinephrine (pg/mL)	Epinephrine (pg/mL)	Normetanephrine Frac Free (nmol/L)	Metanephrine Frac Free (nmol/L)	DHPG Plasma (pg/mL)	DOPA Plasma (pg/mL)
10/21/03	30 (0-30)	444 (70-750)	283 (0-110)	0.28 (< 0.90)	0.21 (< 0.5)		
8/24/04	16 (0-30)	270 (70-750)	76 (0-110)	< 0.20 (< 0.89)	< 0.20 (< 0.49)		
(NIH)10/19/04	8 (3-46)	163 (80-498)	20 (4-83)			811 (518-1408)	1159 (911-2483)
11/23/04	15 (0-30)	448 (70-750)	68 (0-110)	<0.20 (< 0.89)	< 0.20 (< 0.49)		
1/14/05				0.39 (< 0.89)	<0.20 (<0.49)		
1/20/05	<10 (0-30)	326 (70-750)	19 (0-110)				
1/27/05	<10 (0-30)	411 (70-750)	37 (0-110)	0.44 (0.18-0.71)	0.12 (<0.49)		
2/28/05	<10 (0-30)	430 (70-750)	18 (0-110)				
3/15/05				0.20 (0.18-0.71)	0.08 (<0.49)		



Table 2. Urinary Biochemical Tests (Chronological Order, Abnormals = Shaded) in a Patient with Catecholamine-Secreting Enzymes from Unknown Cause

Date	Ur Metanephrines Total (mcg/24hr)	Ur Metanephrines (mcg/24hr)	Ur Norepinephrines (mcg/24hr)	Ur Epinephrines (mcg/24hr)	Ur Dopamine (mcg/24hr)	Ur VMA (mg/24 hr)	Ur Dopamine:Ur Creatinine Ratio (mcg/mcg)
3/28/93	0.42 (0.1-0.9)						
8/27/03	620 (0-1300)	500 (0-400)	55.8 (12.1-85.5)	12.4 (1.7-22.4)	341 (65-400)	2.5 (1.4-6.5)	
8/30/03							
10/7/03							
11/27/03							
12/10/03							
6/14/04							
8/17/04							
8/27/04	750 (95-475)	664 (19-140)	49.0 (15.0-100.0)	25.0 (2.0-24.0)	480 (52-480)	3.7 (1.4-6.5)	
9/29/04	600 (95-475)	414 (19-140)	42.0 (15.0-100.0)	12.0 (2.0-24.0)	476 (52-480)	5.4 (< 6.0)	0.4034 (< 0.28)
10/1/04			192* (15.0-100.0)	72.0* (2.0-24.0)	2424* (52-480)		
10/3/04	1362 (95-475)	1098 (19-140)	66 (15.0-100.0)	18.0 (2.0-24.0)	630 (52-480)	6.6 (<6.0)	0.3728 (< 0.28)
10/5/04			264* (15.0-100.0)	48.0* (2.0-24.0)	1384* (52-480)		
10/7/04	187.3* (95-475)	10.1* (19-140)	127.6* (15.0-100.0)	38.5* (2.0-24.0)	872.3* (52-480)	9.5* (<6.0)	
12/21/04							
12/23/04							
12/27/04	383 (95-475)	241 (19-140)	53 (15.0-100.0)	14 (2.0-24.0)			
1/28/05		142* (19-140)	90* (15.0-100.0)	26* (2.0-24.0)	370* (52-480)	6.4* (<6.0)	
6/05							
7/05							

(Legend: Graytone = Abnormal. *=Extrapolated to 24-hour volume and concentration from spot collections < 24-hr Collections)

Features of HPT event-history data

- Selective patient measurement (both i and t)
- Sustained HPT vs. paroxysmal HPT
- DDX: Many biochemical lab tests possible, errors high
- DDX: Plasma +/- Urinary metanephrines and catecholamines testing?
- Same things not measured every time, unbalanced: epinephrine, norepinephrine, chromogranin A or its fragments, neuropeptide Y, Dopamine B-hydroxylase (DBH), HVA, VMA, dopamine, serotonin
- Diurnal variation normal ... Or flipped in reverse
- Postural hypotension, positional HPT possible
- Spikes during sleep (not) associated with changes in heart rate ... CONTINUED ...

Features of HPT event-history data (cont'd)

- Dietary interferences to tests
- Drug interferences to tests
- Ambulatory blood pressure monitoring (ABPM) “capturing” a paroxysm IFF known stimulus used
- Provocational testing highly sensitive and specific but risky in inexperienced hands, costly (time, \$)
- Missing data if ABPM moves ... Or if acute paroxysm HPT exceeds machine's range
- Labs and/or ABPM missing in a clump ... Or missing only intermittently ... Or selectively drawn
- MD doesn't know when trigger to paroxysm began or ended w.r. to test window
- HPT paroxysm 1-5 minutes if APUD, ABPM interval is 15-20 minutes. Event coding is hit-or-miss.

Event-history model forms extendable to all model classes*

1. Fixed effects

- 1. One-way -- But clinical skepticism about assumption**
- 2. Two-way – But no autocorrelation correction in SW?**

2. Random effects

- 1. Only constant term is random, no heterogeneity in the mean**
- 2. Product of densities for patient's group, not sum of logs, must be computed, individual density like .25 means if group size is ~100, end result is more rounding error than result.**

Event-history model forms extendable to all model classes* (cont'd)

3. Random coefficients

1. Coefficients on exogenous variables may be random or fixed
2. Distribution of parameters may be modelled with other specific characteristics. Mean of distribution of β_j may vary deterministically across patients. Autocorrelation possible

4. Latent classes

1. Most appealing clinical assumptions' compatibility
2. Probability of observing y_{it} given that regime j applies ... Estimate class membership
3. Latent heterogeneity model can be extended by allowing measured influences in the prior probability, due to time-invariant variables ... But time-invariance of variables is clinically problematic

Elegant toolkit, difficult clinical data

- All 4 model forms support all model classes used in cross-sections ... Binary choice, multinomial choice, count data, loglinear models, limited dependent variables models, survival models, switching models and stochastic frontier models
- All 4 model forms require for each group i (=patient) attached to each t^{th} record the variable $t_i = \#$ repeated measures or the within-group $\#$ observations in the group ... Hard to handle
- Missing data confuse event-history set-ups
- Lab measure (t) has different reference range ($t+s$)

Software's treatment of missing data: evils of two lessers?

- Remove observations containing missing values from sample before estimation thus altering the t_i or altering the group mix and/or also the patient mix since missing status is unlikely to be random!
- Leave observations in analysis (depending on SW, model class used). Estimator may bypass missing data.
- Observation count must give group sizes including missing values. Ought to be reported descriptively.
- Fixed effects estimator is shaky if $T_i < 5$ for some groups i.e. patients' time-series
- Random effects estimator may blow up if T_i is large for some groups (e.g. monitored often in treatment)

Canned event-history data-manipulation utilities needed

- Date handling and date-conversion to a whole hierarchy of time expressions
- “Spell” and “interval” matching, i.e. match lab tests on fixed dates with clinical, genetic, HPT, or other medical “event” data that are “around” the same time (clinical/ analyst chooses from among semi-standardized “rules” for matching x_t, y_{t+s})
- Characterize with shape or time-series descriptive parameters each individual’s grouped values. Examples: median, temporal “skew”, distributional parameter just to describe shape of individual’s group values

Canned event-history data- manipulation utilities needed (cont'd)

- **Convert the data from calendar-time-level to event-time-level and to match data between formats**
- **Save, edit and reuse the above matching rules and conventions chosen so dataset can be grown cheaply as clinical data expands on a patient pool**
- **Multiple missing-data options for multiple variables, easy recount and recalc of the groups' ti's as choice of variable causes redefinition of #missing on the fly**
- **Coding multi-episode data by rule set used for matching (since matches' success often drive count of episodes per patient); exploratory graphics too**
- **Coding alphanumeric values uniquely in a hierarchy of levels. Example: Patient names => index variable**

Statisticians' role uncovering "great mimic" apudomas: Event-history data utilities for *faster* clinical analyses

- "Curable in 90% (30-50% if malignant) of patients but eventually lethal in almost 100% if untreated"
- Time to diagnosis 2-7 years (metasizes by then if malignant)
- Cause of malpractice claims: "MD missed the diagnosis ... MD failed to diagnosis apudoma-caused HPT *rapidly* enough to avoid catastrophic disability or death ... MD treated patient with β blocker without preliminary α blockade ... Surgeon manipulated apudoma unknowingly and blew up patient's brain ... BP 255/125 in OR"

Acknowledgements

- William M. Manger, MD, PhD and Ray W. Gifford, MD. Pheochromocytoma: Clinical and Experimental, 2nd ed. Cambridge: 1996.
- Karel Pacak, MD, PhD, DSci, NIH/ NICHD, Chief, Endocrinology Unit and Graeme Eisenhofer, PhD, NIH/ NICHD